Mouse Anti-DMTF1 Monoclonal Antibody (1B7) (V2LY-0425-LY590)

Zhai, X., Wu, Y., Zhang, D., Li, H., Chong, T., & Zhao, J. (2021). MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis. Journal of Bioenergetics and Biomembranes, 53(2), 191-202.

Li, J., Li, G., Qi, Y., Lu, Y., Wang, H., Shi, K., ... & Sui, G. (2021). SRSF5 regulates alternative splicing of DMTF1 pre-mRNA through modulating SF1 binding. RNA biology, 18(sup1), 318-336.

Fry, E. A., & Inoue, K. (2019). c-MYB and DMTF1 in cancer. Cancer investigation, 37(1), 46-65.

Yang, X., Lou, Y., Wang, M., Liu, C., Liu, Y., & Huang, W. (2019). miR‑675 promotes colorectal cancer cell growth dependent on tumor suppressor DMTF1. Molecular Medicine Reports, 19(3), 1481-1490.

Niklaus, N. J., Humbert, M., & Tschan, M. P. (2018). Cisplatin sensitivity in breast cancer cells is associated with particular DMTF1 splice variant expression. Biochemical and biophysical research communications, 503(4), 2800-2806.

Tian, N., Li, J., Shi, J., & Sui, G. (2017). From general aberrant alternative splicing in cancers and its therapeutic application to the discovery of an oncogenic DMTF1 isoform. International Journal of Molecular Sciences, 18(3), 191.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols